<DOC>
	<DOC>NCT03068468</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of intravenously administered BMS-986168 in participants with Progressive Supranuclear Palsy.</brief_summary>
	<brief_title>Study of BMS-986168 in Patients With Progressive Supranuclear Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy, Progressive</mesh_term>
	<criteria>Participants with probable or possible PSP Able to ambulate independently or with assistance Able to tolerate MRI Have reliable caregiver to accompany participant to all study visits Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at screening Participant must reside outside a skilled nursing facility or dementia care facility at the time of screening and admission to such a facility must not be planned Presence of other significant neurological or psychiatric disorders Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neuron disease History of early, prominent rapid eye movement (REM) sleep behavior disorder History of or screening brain MRI scan indicative of significant abnormality Known history of serum or plasma progranulin level less than one standard deviation below the normal patient mean for the laboratory performing the assay Other protocol defined inclusion/exclusion criteria could apply.</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>